Suppr超能文献

铁螯合疗法逆转青少年血色素沉着症终末期心力衰竭:一例报告

Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report.

作者信息

Cooray Shamil D, Heerasing Neel M, Selkrig Laura A, Subramaniam V Nathan, Hamblin P Shane, McDonald Cameron J, McLean Catriona A, McNamara Elissa, Leet Angeline S, Roberts Stuart K

机构信息

Department of Endocrinology & Diabetes, The Alfred Hospital, Melbourne, VIC, 3004, Australia.

Department of Gastroenterology & Hepatology, The Alfred Hospital, Melbourne, VIC, 3004, Australia.

出版信息

J Med Case Rep. 2018 Jan 26;12(1):18. doi: 10.1186/s13256-017-1526-6.

Abstract

BACKGROUND

Juvenile hemochromatosis is the most severe form of iron overloading phenotype. Although rare, it should be suspected in patients who present with hypogonadotropic hypogonadism, diabetes mellitus, or cardiomyopathy without a clear cause.

CASE PRESENTATION

A young Serbian male presenting with end-stage heart failure was referred for extracorporeal membrane oxygenation. An endomyocardial biopsy revealed cytoplasmic iron deposits in myocytes. His condition was stabilized with biventricular assist devices and he was listed for heart transplantation. Iron chelation therapy was commenced and resulted in rapid removal of iron burden. Serial outpatient echocardiograms demonstrated myocardial recovery such that a successful biventricular assist device explant occurred 131 days after initial implant. Targeted gene sequencing revealed a loss-of-function mutation within the HJV gene, which is consistent with juvenile hemochromatosis.

CONCLUSIONS

This rare case of a patient with juvenile hemochromatosis associated with a HJV mutation provides histologic evidence documenting the reversal of associated end-stage heart failure, requiring emergent mechanical circulatory support, with iron chelation therapy.

摘要

背景

青少年血色病是铁过载表型最严重的形式。尽管罕见,但对于出现不明原因的低促性腺激素性性腺功能减退、糖尿病或心肌病的患者应怀疑此病。

病例介绍

一名出现终末期心力衰竭的年轻塞尔维亚男性被转诊接受体外膜肺氧合治疗。心内膜心肌活检显示心肌细胞中有细胞质铁沉积。通过双心室辅助装置使他的病情稳定下来,他被列入心脏移植名单。开始进行铁螯合治疗,铁负荷迅速减轻。系列门诊超声心动图显示心肌恢复,以至于在初次植入双心室辅助装置131天后成功将其取出。靶向基因测序显示HJV基因存在功能丧失突变,这与青少年血色病一致。

结论

这例罕见的与HJV突变相关的青少年血色病患者病例提供了组织学证据,证明铁螯合疗法可逆转相关的终末期心力衰竭,而这种心力衰竭需要紧急机械循环支持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2e7/5787235/df0e25d7cc47/13256_2017_1526_Fig1_HTML.jpg

相似文献

4
[Hereditary hemochromatosis].
Rev Gastroenterol Peru. 2001 Jan-Mar;21(1):42-55.
7
Type 3 hemochromatosis and beta-thalassemia trait.
Eur J Haematol. 2004 May;72(5):370-4. doi: 10.1111/j.1600-0609.2004.00230.x.
8
An Iron-chelating Agent Improved the Cardiac Function in a Patient with Severe Heart Failure Due to Hereditary Hemochromatosis.
Intern Med. 2024 Jan 15;63(2):253-258. doi: 10.2169/internalmedicine.1809-23. Epub 2023 May 17.

引用本文的文献

1
The Quiet Burden of Iron: A Rare Case of Hereditary Hemochromatosis in Pakistan.
Cureus. 2025 Jul 20;17(7):e88355. doi: 10.7759/cureus.88355. eCollection 2025 Jul.
3
Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation.
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):434-442. doi: 10.1182/hematology.2024000568.
4
An Iron-chelating Agent Improved the Cardiac Function in a Patient with Severe Heart Failure Due to Hereditary Hemochromatosis.
Intern Med. 2024 Jan 15;63(2):253-258. doi: 10.2169/internalmedicine.1809-23. Epub 2023 May 17.
5
Hepcidin and Iron in Health and Disease.
Annu Rev Med. 2023 Jan 27;74:261-277. doi: 10.1146/annurev-med-043021-032816. Epub 2022 Jul 29.
6
Juvenile Hemochromatosis due to a Homozygous Variant in the Gene.
Case Rep Pediatr. 2022 Apr 11;2022:7743748. doi: 10.1155/2022/7743748. eCollection 2022.
7
Hidden in Heart Failure.
Eur Cardiol. 2019 Jul 11;14(2):89-96. doi: 10.15420/ecr.2019.19.2. eCollection 2019 Jul.

本文引用的文献

1
2
Interpreting raised serum ferritin levels.
BMJ. 2015 Aug 3;351:h3692. doi: 10.1136/bmj.h3692.
3
Next-generation sequencing: Application of a novel platform to analyze atypical iron disorders.
J Hepatol. 2015 Nov;63(5):1288-93. doi: 10.1016/j.jhep.2015.06.027. Epub 2015 Jul 4.
4
Guidelines for quantifying iron overload.
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):210-5. doi: 10.1182/asheducation-2014.1.210. Epub 2014 Nov 18.
5
Marked hyperferritinemia does not predict for HLH in the adult population.
Blood. 2015 Mar 5;125(10):1548-52. doi: 10.1182/blood-2014-10-602607. Epub 2015 Jan 8.
6
Oral deferiprone for iron chelation in people with thalassaemia.
Cochrane Database Syst Rev. 2013 Aug 21;2013(8):CD004839. doi: 10.1002/14651858.CD004839.pub3.
7
Iron storage disease in Asia-Pacific populations: the importance of non-HFE mutations.
J Gastroenterol Hepatol. 2013 Jul;28(7):1087-94. doi: 10.1111/jgh.12222.
8
Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Ann Hematol. 2012 Sep;91(9):1443-9. doi: 10.1007/s00277-012-1480-8. Epub 2012 May 10.
10
A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation.
J Hepatol. 2011 Aug;55(2):453-8. doi: 10.1016/j.jhep.2011.02.010. Epub 2011 Feb 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验